Figure 2. Comparisons of early-phase and late-phase nausea and vomiting incidence due to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy between patients who received double antiemetic regimens (5HT3 receptor antagonist and dexamethasone) and patients who received triple antiemetic regimens (5HT3 receptor antagonist, dexamethasone, and aprepitant).